Search company, investor...
Synthonics company logo



Corporate Minority | Alive

Total Raised


Last Raised

$2M | 8 yrs ago



About Synthonics

Synthonics is a specialty pharmaceutical company focused on the discovery, development and licensing of drugs that incorporate our proprietary metal coordination chemistry. Metal coordination entails attaching a pharmaceutically acceptable metal, such as zinc, bismuth or magnesium, to a known pharmaceutical agent to create a new and more effective drug. The addition of the metal changes the way the drug is absorbed or delivered without altering the action of the underlying drug.

Headquarters Location

2220 Kraft Drive Suite 2225

Blacksburg, Virginia, 24060,

United States


Missing: Synthonics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Synthonics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Synthonics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Synthonics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

1,568 items

Synthonics Patents

Synthonics has filed 13 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Cannabinoids
  • Colloidal chemistry
patents chart

Application Date

Grant Date


Related Topics




Glucocorticoids, Pregnanes, Abandoned drugs, Fluoroarenes, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Glucocorticoids, Pregnanes, Abandoned drugs, Fluoroarenes, Monoclonal antibodies



Latest Synthonics News

RS Biotherapeutics Reports Positive Results From Proof-of-Concept Trial for First Investigational Compound

Jul 11, 2022

Cumberland, Maryland, UNITED STATES CUMBERLAND, Md., July 11, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce positive results from its proof-of-concept study for its first investigational compound, RSBT-001. RSBT-001 is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid (CBDa) complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. RS BioTherapeutics conducted the study in conjunction with RSBT-001 development partner, Synthonics, Inc., and Marshall University using a mouse model of pulmonary inflammation. The proof of concept model was created by instilling E. coli derived lipopolysaccharide (LPS) intranasally. Anti-inflammatory response was determined by measuring a series of cytokines known to be highly expressed in response to pulmonary inflammation. RSBT-001 was dosed at 1 mg/kg intranasally and its performance was measured against a positive control, dexamethasone, at 2.5 mg/kg and 10.0 mg/kg dosed intranasally; a negative control (LPS only); and vehicle only. Both RSBT-001 and dexamethasone were administered in a single dose 8 hours after insult. Cytokine measurements were made with mouse lung homogenate at 12 hours, 24 hours, and 48 hours after test material administration. Justin Molignoni, CRNP, Chief Strategy Officer and Co-Chair of the RS BioTherapeutics Joint Development Committee said, “The data from the proof-of-concept trial clearly indicates that RSBT-001 reduces cytokine level, and that this cytokine reduction is appropriately transient. This supports the theory that RSBT-001 can reduce the harmful effects of an overstimulated immune system, which causes damaging inflammation, but does not completely suppress the immune response, which is important to retain in order to continue to fight off the insult or infection.” Thomas Piccariello, Ph.D., Co-Chair of the RS BioTherapeutics Joint Development Committee and Co-Founder, President and Chief Science Officer of Synthonics, Inc. said, “Our conclusions are that RSBT-001 approached normalization of IL6, IFNγ, IL-12p70 and IL-1β relative to baseline at the 12 and 24 hours timepoints. Moreover, RSBT-001’s response was similar to dexamethasone’s 2.5 mg/kg responses. In this trial, RSBT-001 demonstrated exactly what we want to accomplish with any anti-inflammatory agent:  down regulate cytokines to the appropriate therapeutic level but not eliminate cytokines altogether. Completely eliminating cytokine expression is what corticosteroids, like dexamethasone, can do, which allows secondary infections to occur.” Adding to the discussion, Hongwei Yu, Ph.D., a professor in the Marshall University School of Medicine and one of the lead researchers on the study noted, “The results of the proof-of-concept study for RSBT-001 were exciting. We are looking forward to participating in additional studies to determine the precise dosing of RSBT-001 that is most effective at preventing lung inflammation as well as its safety and adverse event profile.” RS BioTherapeutics has initiated a second study with Marshall to further evaluate the impact of RSBT-001 on pulmonary inflammation. About RS BioTherapeutics Founded by experts in pulmonary diseases and the endocannabinoid system, RS BioTherapeutics is a wholly owned subsidiary of Real Science Holdco LLC. The company’s mission is to harness its strong and thorough understanding of the Endocannabinoid System in the research, development, and commercialization of forward-thinking interventions to address chronic and acute pulmonary inflammation-based diseases. More information on RS Biotherapeutics can be found at . About Synthonics Synthonics, Inc. is a privately-held specialty pharmaceutical company focused on the discovery and development of patentable drugs that incorporate its proprietary metal coordination chemistry. It binds metals to known pharmaceutical agents to create new products that are better absorbed and thus have greater therapeutic benefits than their predecessors. More information on Synthonics can be found at . Media Contact:

Synthonics Frequently Asked Questions (FAQ)

  • Where is Synthonics's headquarters?

    Synthonics's headquarters is located at 2220 Kraft Drive, Blacksburg.

  • What is Synthonics's latest funding round?

    Synthonics's latest funding round is Corporate Minority.

  • How much did Synthonics raise?

    Synthonics raised a total of $7.97M.

  • Who are the investors of Synthonics?

    Investors of Synthonics include Recipharm.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.